Podcasts about Atrophy

In this powerful episode, author Jack McMahon joins Amb. Elisha to share his journey of resilience, fatherhood, and the inspiration behind his thought-provoking book Atrophy and Asymptotes.   After the tragic loss of his brother during the pandemic, Jack reflects on family, the duties of fatherhood versus citizenship, and how personal struggles shaped his writing.   Jack opens up about authoritarian drift in America, how we should respond to injustice with reason over rage, and the principles we must pass on to future generations.   His book—written both as a legacy for his daughter and a call to society—challenges readers to confront uncomfortable truths, draw firm lines in their values, and never lose sight of hope.   If you're looking for a conversation that blends personal storytelling, philosophy, and social insight, this episode will leave you both inspired and challenged.  

Multiple system atrophy is a rare, sporadic, adult-onset, progressive, and fatal neurodegenerative disease. Accurate and early diagnosis remains challenging because it presents with a variable combination of symptoms across the autonomic, extrapyramidal, cerebellar, and pyramidal systems. Advances in brain imaging, molecular biomarker research, and efforts to develop disease-modifying agents have shown promise to improve diagnosis and treatment. In this episode, Casey Albin, MD speaks with Tao Xie, MD, PhD, author of the article “Multiple System Atrophy” in the Continuum® August 2025 Movement Disorders issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Xie is director of the Movement Disorder Program, chief of the Neurodegenerative Disease Section in the department of neurology at the University of Chicago Medicine in Chicago, Illinois. Additional Resources Read the article: Multiple System Atrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Full episode transcript available here Dr. Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Albin: Hello everyone, this is Dr Casey Albin. Today I'm interviewing Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Xie: Thank you so much, Dr Albin. My name is Tao Xie, and sometimes people also call me Tao Z. I'm a mood disorder neurologist, professor of neurology at the University of Chicago. I'm also in charge of the mood disorder program here, and I'm the section chief in the neurodegenerative disease in the Department of Neurology at the University of Chicago Medicine. Thank you for having me, Dr Albin and Dr Okun and the American Academy of Neurology. This is a great honor and pleasure to be involved in this education session. Dr Albin: We are delighted to have you, and thank you so much for the thoughtful approach to the diagnosis and management. I really want to encourage our listeners to check out this article. You know, one of the things that you emphasize is multiple system atrophy is a fairly rare condition. And I suspect that clinicians and trainees who even have a fair amount of exposure to movement disorders may not have encountered that many cases. And so, I was hoping that you could just start us off and walk us through what defines multiple system atrophy, and then maybe a little bit about how it's different from some of the more commonly encountered movement disorders. Dr Xie: This is a really good question, Dr Albin. Indeed, MSA---multisystem atrophy----is a rare disease. It is sporadic, adult-onset, progressive, fatal neurodegenerative disease. By the name MSA, multisystem atrophy. Clinically, it will present with multiple symptoms and signs involving multiple systems, including symptoms of autonomic dysfunction and symptoms of parkinsonism, which is polyresponsive to the levodopa treatment; and the symptom of cerebellar ataxia, and symptom of spasticity and other motor and nonmotor symptoms. And you may be wondering, what is the cause- underlying cause of these symptoms? Anatomically, we can find the area in the basal ganglia striatonigral system, particularly in the putamen and also in the cerebellar pontine inferior, all of the nuclear area and the specific area involved in the autonomic system in the brain stem and spinal cord: all become smaller. We call it atrophy. Because of the atrophy in this area, they are responsible for the symptom of parkinsonism if it is involved in the putamen and the cerebral ataxia, if it's involved in the pons and cerebral peduncle and the cerebellum. And all other area, if it's involved in the autonomic system can cause autonomic symptoms as well. So that's why we call it multisystem atrophy. And then what's the underlying cellular and subcellular pathological, a hallmark that is in fact caused by misfolded alpha-synuclein aggregate in the oligodontia site known as GCI---glial cytoplasmic increasing bodies---in the cells, and sometimes it can also be found in the neuronal cell as well in those areas, as mentioned, which causes the symptom. But clinically, the patient may not present all the symptoms at the same time. So, based on the predominant clinical symptom, if it's mainly levodopa, polyresponsive parkinsonism, then we call it MSAP. If it's mainly cerebellar ataxia, then we call it MSAC. But whether we call it MSP or MSC, they all got to have autonomic dysfunction. And also as the disease progresses, they can also present both phenotypes together. We call that mixed cerebellar ataxia and parkinsonism in the advanced stage of the disease. So, it is really a complicated disease. The complexity and the similarity to other mood disorders, including parkinsonism and the cerebellar ataxia, make it really difficult sometimes, particularly at the early stages of disease, to differentiate one from the other. So, that was challenging not only for other professionals, general neurologists and even for some movement disorder specialists, that could be difficult particularly if you aim to make an accurate and early diagnosis. Dr Albin: Absolutely. That is such a wealth of knowledge here. And I'm going to distill it just a little bit just to make sure that I understand this right. There is alpha-synuclein depositions, and it's really more widespread than one would see maybe in just Parkinson's disease. And with this, you are having patients present with maybe one of two subtypes of their clinical manifestations, either with a Parkinson's-predominant movement disorder pattern or a cerebellar ataxia type movement disorder pattern. Or maybe even mixed, which really, you know, we have to make things quite complicated, but they are all unified and having this shared importance of autonomic features to the diagnosis. Have I got that all sort of correct? Dr Xie: Correct. You really summarize well. Dr Albin: Fantastic. I mean, this is quite a complicated disease. I would pose to you sort of a case, and I imagine this is quite common to what you see in your clinic. And let's say, you know, a seventy-year-old woman comes to your clinic because she has had rigidity and poor balance. And she's had several falls already, almost always from ground level. And her family tells you she's quite woozy whenever she gets up from the chair and she tends to kind of fall over. But they noticed that she's been stiff,and they've actually brought her to their primary care doctor and he thought that she had Parkinson's disease. So, she started levodopa, but they're coming to you because they think that she probably needs a higher dose. It's just not working out very well for her. So how would you sort of take that history and sort of comb through some of the features that might make you more concerned that the patient actually has undiagnosed multiple systems atrophy? Dr Xie: This is a great case, because we oftentimes can encounter similar cases like this in the clinic. First of all, based on the history you described, it sounds like an atypical parkinsonism based on the slowness, rigidity, stiffness; and particularly the early onset of falls, which is very unusual for typical Parkinson disease. It occurs too early. If its loss of balance, postural instability, and fall occurred within three years of disease onset---usually the motor symptom onset---then it raises a red flag to suspect this must be some atypical Parkinson disorders, including multiple system atrophy. Particularly, pou also mentioned that the patient is poorly responsive to their levodopa therapy, which is very unusual because for Parkinson disease, idiopathic Parkinson disease, we typically expect patients would have a great response to the levodopa, particularly in the first 5 to 7 years. So to put it all together, this could be atypical parkinsonism, and I could not rule out the possibility of MSA. Then I need to check more about other symptoms including autonomic dysfunction, such as orthostatic hypertension, which is a blood pressure drop when the patient stands up from a lying-down position, or other autonomic dysfunctions such as urinary incontinence or severe urinary retention. So, in the meantime, I also have to put the other atypical Parkinson disorder on the differential diagnosis, such as PSP---progressive supranuclear palsy---and the DLBD---dementia with Lewy body disease.---Bear this in mind. So, I want to get more history and more thorough bedside assessment to rule in or rule out my diagnosis and differential diagnosis. Dr Albin: That's super helpful. So, looking for early falls, the prominence of autonomic dysfunction, and then that poor levodopa responsiveness while continuing to sort of keep a very broad differential diagnosis? Dr Xie: Correct. Dr Albin: One of the things that I just have to ask, because I so taken by this, is that you say in the article that some of these patients actually have preservation of smell. In medical school, we always learn that our Parkinson's disease patients kind of had that early loss of smell. Do you find that to be clinically relevant? Is that- does that anecdotally help? Dr Xie: This is a very interesting point because we know that the loss of smelling function is a risk effect, a prodromal effect, for the future development of Parkinson disease. But it is not the case for MSA. Strange enough, based on the literature and the studies, it is not common for the patient with MSA to present with anosmia. Some of the patients may have mild to moderate hyposmia, but not to the degree of anosmia. So, this is why even in the more recent diagnosis criteria, the MDS criteria published 2022, it even put the presence of anosmia in the exclusion criteria. So, highlight the importance of the smell function, which is well-preserved for the majority in MSA, into that category. So, this is a really interesting point and very important for us, particularly clinicians, to know the difference in the hyposmia, anosmia between the- we call it the PD, and the dementia Lewy bodies versus MSA. Dr Albin: Fascinating. And just such a cool little tidbit to take with us. So, the family, you know, you're talking to them and they say, oh yes, she has had several fainting episodes and we keep taking her to the primary care doctor because she's had urinary incontinence, and they thought maybe she had urinary tract infections. We've been dealing with that. And you're sort of thinking, hm, this is all kind of coming together, but I imagine it is still quite difficult to make this diagnosis based on history and physical alone. Walk our listeners through sort of how you're using MRI and DAT scan and maybe even some other biomarkers to help sort of solidify that diagnosis. Dr Xie: Yeah, that's a wonderful question. Yeah. First of all, UTI is very common for patients with MSA because of urinary retention, which puts them into a high risk of developing frequent UTI. That, for some patients, could be the very initial presentation of symptoms. In this case, if we check, we say UTI is not present or UTI is present but we treat it, then we check the blood pressure and we do find also hypertension---according to new diagnosis criteria, starting drop is 20mm mercury, but that's- the blood pressure drop is ten within three minutes. And also, in the meantime the patients present persistent urinary incontinence even after UTI was treated. And then the suspicion for MS is really high right at this point. But if you want increased certainty and a comfortable level on your diagnosis, then we also need to look at the brain MRI mark. This is a required according to the most recent MDS diagnosis criteria. The presence of the MRI marker typical for MSA is needed for the diagnosis of clinically established MSA, which holds the highest specificity in the clinical diagnosis. So then, we have- we're back to your question. We do need to look at the brain MRI to see whether evidence suggestive of atrophy around the putamen area, around the cerebellar pontine inferior olive area, is present or not. Dr Albin: Absolutely. That's super helpful. And I think clinicians will really take that to sort of helping to build a case and maybe recognizing some of this atypical Parkinson's disease as a different disease entity. Are there any other biomarkers in the pipeline that you're excited about that may give us even more clarity on this diagnosis? Dr Xie: Oh, yeah. This is a very exciting area. In terms of biomarker for the brain imaging, particularly brain MRI, in fact, today there's a landmark paper just published in the Java Neurology using AI, artificial intelligence or machine learning aid, diagnoses a patient with parkinsonism including Parkinson's disease, MSA, and PSP, with very high diagnostic accuracy ranging from 96% to 98%. And some of the cases even were standard for autopsy, with pathological verification at a very high accurate rate of 93.9%. This is quite amazing and can really open new diagnosis tools for us to diagnose this difficult disease; not only in an area with a bunch of mood disorder experts, but also in the rural area, in the area really in need of mood disorder experts. They can provide tremendous help to provide accurate, early diagnosis. Dr Albin: That's fantastic and I love that, increasing the access to this accurate diagnosis. What can't artificial intelligence do for us? That's just incredible. Dr Xie: And also, you know, this is just one example of how the brain biomarker can help us. Theres other---a fluid biomarker, molecular diagnostic tools, is also available. Just to give you an example, one thing we know over the past couple years is skin biopsy. Through the immunofluorescent reaction, we can detect whether the hallmark of abnormally folded, misfolded, and the phosphorate, the alpha-synuclein aggregate can be found just by this little pinch of skin biopsy. Even more advanced, there's another diagnosis tool we call the SAA, we call the seizure amplification assay, that can even help us to differentiate MSA from other alpha-synucleinopathy, including Parkinson disease and dementia with Lewy bodies. If we get a little sample from CSF, spinal cerebral fluids, even though this is probably still at the early stage, a lot of developments still ongoing, but this, this really shows you how exciting this area is now. We're really in a fast forward-moving path now. Dr Albin: It's really incredible. So, lots coming down the track in, sort of, MRI, but also with CSF diagnosis and skin biopsies. Really hoping that we can hone in some of those tools as they become more and more validated to make this diagnosis. Is that right? Dr Xie: Correct. Dr Albin: Amazing. We can talk all day about how you manage these in the clinic, and I really am going to direct our listeners to go and read your fantastic article, because you do such an elegant job talking about how this takes place in a multidisciplinary setting, if at all possible. But as a neurointensivist, I was telling you, we have so much trouble in the hospital. We have A-lines, and we have the ability to get rapid KUBs to look at Ilias, and we can have many people as lots of diagnosis, and we still have a lot of trouble treating autonomiclike symptoms. Really, really difficult. And so, I just wanted to kind of pick your brain, and I'll start with just the one of orthostatic hypotension. What are some of the tips that you have for, you know, clinicians that are dealing with this? Because I imagine that this is quite difficult to do without patients. Dr Xie: Exactly. This is indeed a very difficult symptom to deal with, particularly at an outpatient setting. But nowadays with the availability of more medication---to give an example, to treat patients with orthostatic hypertension, we have not only midodrine for the cortisol, we also have droxidopa and several others as well. And so, we have more tools at hand to treat the patient with orthostatic hypertension. But I think the key thing here, particularly for us to the patient at the outpatient setting: we need to educate the patient's family well about the natural history of the disease course. And we also need to tell them what's the indication and the potential side effect profile of any medication we prescribe to them so that they can understand what to expect and what to watch for. And in the meantime, we also need to keep really effective and timely communication channels, make sure that the treating physician and our team can be reached at any time when the patient and family need us so that we can be closely monitoring, their response, and also monitoring potential side effects as well to keep up the quality of care in that way. Dr Albin: Yeah, I imagine that that open communication plays a huge role in just making sure that patients are adapting to their symptoms, understanding that they can reach out if they have refractory symptoms, and that- I imagine this takes a lot of fine tuning over time. Dr Xie: Correct. Dr Albin: Well, this has just been such a delight to get to talk to you. I really feel like we could dive even deeper, but I know for the sake of time we have to kind of close out. Are there any final points that you wanted to share with our listeners before we end the interview? Dr Xie: I think for the patients, I want them to know that nowadays with advances in science and technology, particularly given a sample of rapid development in the diagnostic tools and the multidisciplinary and multisystemic approach to treatment, nowadays we can make an early and accurate diagnosis of the MSA, and also, we can provide better treatment. Even though so far it is still symptomatically, mainly, but in the near future we hope we can also discover disease-modifying treatment which can slow down, even pause or prevent the disease from happening. And for the treating physician and care team professionals, I just want them to know that you can make a difference and greatly help the patient and the family through your dedicated care and also through your active learning and innovative research. You can make a difference. Dr Albin: That's amazing and lots of hope for these patients. Right now, you can provide really great care to take care of them, make an early and accurate diagnosis; but on the horizon, there are really several things that are going to move the field forward, which is just so exciting. Again today, I've been really greatly honored and privileged to be able to talk to Dr Tao Xie about his article on diagnosis and management of multiple system atrophy, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes for this and other issues. And thank you again to our listeners for joining us today. Dr Xie: Thank you so much for having me. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In this episode of Limb Lengthening LIVE, we're going to have patients who have contributed content share updates. Plus a few announcementsAudio Podcast - will be available within 24-48hrs after stream endsTimestamps - 0:00 – Intro & Guest Introductions2:15 – Aaron's X-Ray Update & Progress (6.1 cm → 7.4 cm goal)6:00 – Walking Timeline, Nerve Pain & Physical Therapy8:32 – Nailed Legs Update: Bone Stimulator, HGH & Healing Speed11:53 – Codeman Red Joins: Surgery with Dr. Wallace & 62.5 mm Progress13:45 – Nerve Pain Solutions (Supplements vs Medications)16:20 – Stretching Challenges & Finding Quality PT22:20 – Lifestyle Changes & Noticing New Height28:50 – Aesthetics, Atrophy & Planning Final Height Goal38:45 – Aiden Joins: Hitting 70 mm & Managing Tightness47:00 – Master Distractor Update: Cooking, Walking & 82 mm Goal52:55 – Planning Tibias Next & Discussion on Quadrilateral Safety58:40 – Audience Q&A: Walking Gait, Nail Sizes & Supplements1:11:30 – Big Question: Is 5'10" → 6'2" Worth It?1:15:30 – Recovery Timeline for Quadrilateral Lengthening (~7 Months)1:16:30 – Australian Media Announcement: Patients Wanted for Interview1:16:50 – Final Patient Advice & Outro_______________________Find Links to Everything Here and Below: https://sleekbio.com/cyborg4life

Cosmic Killers, Parallel Worlds, & Biblical Secrets Revealed!Josh Peck discusses the universe, multiverse, and what could destroy them.To get the audio-only podcast version of full videos and Josh Peck's blog, which includes original articles, show notes, and more, subscribe to Josh's Substack at http://joshpeck.substack.comDonate: http://PayPal.me/JoshPeckDisclosureCashApp: $JoshScottPeckOr send in your donation to:P.O. Box 270123Oklahoma City, OK 73137

Drs. Patel and Armstrong discuss how they are integrating FDA-approved therapies into geographic atrophy care. They share their perspectives on emerging treatments, including the potential for combination or staged approaches.

AI: BRAIN ATROPHY, RACHEL  LOMASKY.

AI: BRAIN ATROPHY, RACHEL  LOMASKY. CONTINUED 1978

Drs. M. Ali Khan and Ajay Kuriyan join to discuss the current sentiment in the retina community regarding geographic atrophy treatment, specifically complement inhibition. Relevant Financial Disclosures: Dr. Sridhar has consulted for both Apellis and Iveric Bio in the past 3 years. You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

The State of Geographic Atrophy Around the Globe: Part 1 of 2 DES: For what pathophysiologic reasons is targeting the complement pathway a viable therapeutic route for treating geographic atrophy? And which pipeline therapeutic approaches could be useful to patients in the future? Anat Loewenstein, MD is joined by a world-class trio of retina specialists—Daniel Ting, MD, PhD; Paulo Eduardo Stanga, MD; and Patricio G. Schlottmann, MD—for a discussion exploring the state of play in GA from a global perspective. This podcast is part 1 of 2. 

Anat Loewenstein, MD; Paulo Eduardo Stanga, MD; Patricio G. Schlottmann, MD and Daniel Ting, MD, PhD, pick up where they left off in our previous episode, further exploring the value of setting expectations for patients with GA in nations without wide access to complement inhibitors. They also comment on which therapeutic approaches can be employed now and look toward possible forthcoming treatments. This podcast is part 2 of 2. 

Drs. Modi and Dedania discuss imaging, biomarkers, and diagnosis in geographic atrophy, as well as current therapies and those in late stage clinical trials.

In the second episode of a three-part series on the key factors that limit healthspan, Dr. Erin Faules and Dr. Mike Stone explore the role of muscle loss, chronic inflammation, and cancer in accelerating decline—and what you can do about it. Key topics include: How muscle mass and strength relate to longevity Tools for assessing body composition and early signs of sarcopenia Common blockers to building muscle—including underfueling, overtraining, and hormonal factors The role of inflammation in aging, disease risk, and immune dysfunction How to interpret CRP and other lab markers in context A look at new cancer screening technologies (like liquid biopsy and full-body MRI) The importance of individualized, risk-informed decision-making in preventive care

From The Archives on Our Website at: https://biselliano.info/2022/02/12/who-is-dr-berg-what-does-he-teach-guide-to-alternative-holistic-medicine-natural-remedies/*****Thank you for tuning in & showing your support!DISCLAIMER: Not all of the views expressed by our Hosts nor our Guests represent EA Truth Media as a whole! We invite you to chat with us on social media about our shows using hashtag #EATruthRadioSupport The Eternal Truth + Election Integrity by using Promo Code 'ETERNAL' at https://mypillow.eamedia.online Checkout ... Grab The Latest Best Deals on Hiqh Quality MyPillow Products ...*** Visit our Media Site at www.EternalAffairsMedia.com **** GRAB OUR PUBLISHER'S FREE SURVIVAL EBOOK = https://survival.biselliano.info !!! *** NEED PRAYER? Join Our Prayer ARMY Email List: * https://prayer.eamedia.online*** Please Consider Planting A SEED IN OUR MINISTRY! **** https://donate.eamedia.online* https://patreon.eamedia.online* https://cash.eamedia.online ($eamediaonline) * CRYPTOCURRENCY ~ ~ ~ https://strike.me/watchmancbiz*** Sign up for our FREE Email Newsletter! **** https://breaking.eternalaffairsmedia.com*** THERE IS SO MUCH TO OFFER ON THE SITE *** * Learn more with Our LinkTree ~ ~ https://links.eamedia.online- -- *** NEW TRUTH PREMIUM *** on EA Truth Media Website * Exclusive Premium Content & Less Ads ~ ONLY $3.99 ~ Click Here ----- https://premium.eamedia.online- - THE TRUTH SHALL PREVAIL ~ WE ARE THE STORM! Our Independent Media Operation & Prophetic End Times Ministry has been online faithfully providing much valuable TRUTH for 15 years now! You're Gonna KNOW GOD DID IT!!! Eternal Affairs Media ™ is an alternative to mainstream mockingbird fake news propaganda media! We have since morphed into a partial prophetic end times ministry during these Biblical Days!!!! We are on the frontlines leading the fight against the Fake News Mockingbird Media, but we are still growing & need your support in whatever way that means to you and God Leads You :) *****Check out our Online Store and get some COOL GEAR!https://store.eamedia.onlineIf there is anything you'd like to see that isn't there, message us! We wish to hear from you!We Need To FILL IMMEDIATE ASSOCIATE POSITIONS: https://jointeam.eamedia.online !!!!!*****People are waking up! This is THE GREAT AWAKENING vs. The Great Reset ... Pick a side ... No lukewarm allowed in Heaven! God bless you & your loved ones! GOD BLESS THE REPUBLIC OF AMERICA! Victory, Restoration, Restitution & Vindication Incoming - Get Ready!This is GOING TO BE BIBLICAL ... and IT'S HAPPENING! YOU CAN FEEL IT & THOSE AWAKE CAN SEE IT! PRAY!! Grab Emergency Food Kit at: https://prepare.eamedia.online*** DISCLAIMER *** Some of our shows contain AI as well as speculative content ... we encourage you to do your own research & seek the truth for yourself! Thank you! Have a Question, Comment, Suggestion, Prayer Request? Heck! Do you just want to SAY HI? ... hit us up today!Support the show

Want to Start or Grow a Successful Business? Schedule a FREE 13-Point Assessment with Clay Clark Today At: www.ThrivetimeShow.com   Join Clay Clark's Thrivetime Show Business Workshop!!! Learn Branding, Marketing, SEO, Sales, Workflow Design, Accounting & More. **Request Tickets & See Testimonials At: www.ThrivetimeShow.com  **Request Tickets Via Text At (918) 851-0102   See the Thousands of Success Stories and Millionaires That Clay Clark Has Helped to Produce HERE: https://www.thrivetimeshow.com/testimonials/ Download A Millionaire's Guide to Become Sustainably Rich: A Step-by-Step Guide to Become a Successful Money-Generating and Time-Freedom Creating Business HERE: www.ThrivetimeShow.com/Millionaire   See Thousands of Case Studies Today HERE: www.thrivetimeshow.com/does-it-work/  

This episode is another retina-focused EyeNovation episode featuring Prof. Robyn Guymer who presented an in-depth discussion on the SIRE sign, assessment of visual function in Geographic atrophy and also current GA trials and treatments.   YouTube link: https://youtu.be/p-R4_OsuGKE  

Examine the vulva in menopause consultations Biopsy is important for diagnosis Differentiating vulval conditions Treatment with potent topical steroids Referral considerations The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. Do you always examine the vulva in the menopause consult, or would you wait and see if the patient doesn’t have the expected response to vaginal oestrogen? How do we differentiate between lichen sclerosus, lichen planus, or lichen simplex chronicus? Do you think the itch of lichen sclerosus responds to vaginal oestrogen? Could you give this to a woman, and she’s going to get better, and you’ll never know that she had lichen sclerosus? What treatments do you use, and for how long? Can you take a punch biopsy from one site - the site that you think is perhaps the easiest to biopsy or looks the most affected? Is a 3 mm punch biopsy big enough? Do you have to pop a suture in? How do you manage the care of that biopsy after you’ve done it? Is referring to a dermatologist or gynaecologist better for biopsy? Which steroids do you use, for how long, and what results do you expect? How does a woman present with lichen planus? Host: Dr Marita long | Total Time: 23 mins Expert: Dr Terri Foran, Sexual Health Physician Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

(00:00-18:30) Talking sports talk radio over the course of the last 25 years with Bob Ramsey. Brian McKenna becoming more charitable after he got sick. Charity becoming his calling. Coach Schertz & SLU basketball.(18:38-25:01) Baby making music. The players are starting to arrive to the property. James Toombs sitting down with the fellas.(25:11-50:52) Ken "Iggy" Strode sitting down at the dais. Iggy's celebrity guests. Atrophy is setting in. Does Iggy have a date for Plowsy's wedding? Progress on his book. The Iggy/Jenna Fischer story.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Vaginal oestrogen is safe at any age, including over 70, with regular review Use vaginal oestrogen cautiously in younger women; rule out other causes such like vulval dermatitis In breast cancer survivors, vaginal oestrogen is off-label; prefer estriol and involve oncology Vaginal DHEA (Intrarosa) is effective with minimal absorption; lacks long-term safety data; no washout needed when switching The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. What are the main symptoms for women with vaginal atrophy, and what is the general approach when a woman comes to talk about these symptoms? How long can women use vaginal oestrogen for? If you saw a woman over the age of 70, would you feel comfortable allowing her to continue using vaginal oestrogen? Is it safe to use vaginal oestrogen in a younger woman who might be breastfeeding or taking the combined oral contraceptive pill and experiencing vaginal dryness or discomfort? Do you need to take the same precautions for side effects as you would with systemic hormone therapy? For example, if there was a woman who was prone to venous thromboembolism (VTE), is it safe for her to use vaginal oestrogen? Is there any role for vaginal oestrogen in reducing the frequency of recurrent genital herpes outbreaks? Are there situations where you would use vaginal oestrogen in combination with a non-hormonal product for better results? Thoughts on laser treatments, microneedling, or PRP for vaginal or vulval symptoms? In women who present with urethral caruncles, is there a role for vaginal oestrogen as part of the treatment? How long would you try using vaginal oestrogen for that? What about the doses of oestrogen when treating someone who's had breast cancer? What do we have to be mindful of? What about women with a history of endometrial, cervical, or vulval cancer? Can we use vaginal oestrogen if they've got symptoms? Can DHEA (Intrarosa) be used safely in women with a history of cancer? For women without breast cancer, when would you use DHEA instead of oestrogen? Would you ever use both oestrogen and DHEA together? What about using DHEA in conjunction with systemic menopausal hormone therapy? Are there any thoughts around the improvements in libido with the use of DHEA? If you had tried someone on Ovestin (estriol) and wanted to switch to Intrarosa, is a washout period required before starting? Host: Dr Marita long | Total Time: 33 mins Expert: Dr Terri Foran, Sexual Health Physician Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.

Interview with MD/PhD fellow, Nicholas Brennan

More information about Brain Lenses at brainlenses.com.Paid BL supporters receive an additional episode of the show each week.Read the written version of this episode: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit brainlenses.substack.com/subscribe

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE/IPCE information, and to apply for credit, please visit us at PeerView.com/GEH865. CME/COPE/IPCE credit will be available until March 20, 2026.Improving the Patient Experience in Geographic Atrophy: Are You Putting the Latest Advances Into Practice? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Apellis Pharmaceuticals, Inc. and Astellas.Disclosure information is available at the beginning of the video presentation.

Send us a textIn this episode of the ZAGA Centers Podcast, Dr. Safa Tahmasebi challenges the conventional approach to severe maxillary atrophy. His session, “To Zygoma or Not to Zygoma? A Modern Approach to Severe Atrophy,” explores innovative and conservative alternatives before considering complex surgical solutions. He discusses treatment planning, protocol development, and patient-centered decision-making to optimize long-term outcomes.Curious about the latest insights from the Edentulism Conference 2025? Discover more on our website: https://bit.ly/EdentulismConference2025BCNOr engage directly with our ZAGA Community by joining the ZAGA Circle, our WhatsApp group, where knowledge and experience in full mouth rehabilitation are shared daily: https://chat.whatsapp.com/HAA4vAj6nl4ApY02m9zMgS

Membership Specials HEREDownload The Swolenormous App HereMERCH - PapaSwolio.comWatch the full episodes here: Subscribe on RumbleSubmit A Question⁠ For The Show Use Code "GTTFG" to get 10% OFF ALL MERCH!Get On Papa Swolio's Email ListDownload The 7 Pillars Ebook Try A Swolega Class From Inside Swolenormous X Get Your Free $10 In Bitcoin   Questions? Email Us: Support@Swolenormous.com

Gary discusses several recent examples about people believing absurd things just because of something they saw online. AI is only as good as the database it searches, and if errors exist in the data, the answers the AI gives will always be wrong. People need to learn to be discerning and check information out before repeating it.

Atrophy's Media: Instagram: https://www.instagram.com/official_atrophyYouTube: https://www.youtube.com/@AtrophyEPK: https://epkbuilder.com/epks/atrophyFacebook: https://www.facebook.com/profile.php?id=61554978797881

With two FDA-approved treatments now available for geographic atrophy, an advanced form of dry age-related macular degeneration, we'll explore how to navigate treatment options, engage in shared decision-making with your healthcare team, and maximize your eye health. February is Low Vision Awareness Month, so we'll also discuss support options for those living with vision loss.

Now is the time to start redirecting our gaze from competitions and accomplishing greatness on a stage serving judges that do not matter to our shops, and refocusing our attention on the judges that truly matter. Our customers.  Today on Shift Break we will be talking about the phrase "Every customer is a judge". I used to hear it being spoken when I was involved in competitions in the early 2000s. How can we use the same energy we would put into a championship performance on behalf of of the customer and the experience they have in our shop?   Related episodes:  340 : Encore Episode of “10 Reasons to Love the Customer”! 298 : A Trophy, or Atrophy?  151 : How to Respond and React to Negative Feedback : 5 Step Process 259 : Solving Toxic Customer Service Culture 181 : Organizational Self-Knowledge Icing on the Cake: Competitions vs. the Shop     ATTENTION CAFE OWNERS w/ 2+ Years of running your brick and mortar.... - LOOKING FOR A COMMUNITY OF SUPPORT, ACCOUNTABILITY, INSIGHT, AND ENCOURAGEMENT?  - The Key Holder Coaching Group master-mind are now taking new applicants for our 4th cohort launching in march!  Click below to fill out your application now! KEY HOLDER COACHING APPLICATION   INTERESTED IN CONSULTING AND COACHING? If you are a cafe owner and want to work one on one with me to bring your shop to its next level and help bring you joy and freedom in the process then email  chris@keystothshop.com of book a free call now:  https://calendly.com/chrisdeferio/30min    Thank you to out sponsors! Everything you need for back of the house operations https://rattleware.qualitybystainless.com/   The best and most revered espresso machines on the planet: www.lamarzoccousa.com  

In this episode of My Thyroid Health, learn more about thyroid gland shrinking – known as atrophy, and a condition known as atrophic thyroiditis. What you will learn: What is thyroid atrophy? What's the difference between Hashimoto's, Graves' disease, and atrophic thyroiditis? What are the symptoms of atrophic thyroiditis? How is atrophic thyroiditis diagnosed? How is atrophic thyroiditis treated? ‍ Check out our blog and read the full article here: https://www.palomahealth.com/learn/thyroid-atrophy About Paloma Health: ⁠⁠Paloma Health⁠⁠⁠⁠⁠⁠⁠⁠is an online medical practice focused exclusively on treating hypothyroidism. From online visits with your provider to easy prescription management and lab orders, we create personalized treatment plans for you.  Become a member⁠, or try our at-home test kit and experience a whole new level of hypothyroid care. Use code PODCAST to save $30 at checkout. Disclaimer: The $30 discount is only valid for first-time Paloma Health members and test kit users. Coupon must be entered at the time of checkout.  Become a Paloma Member: https://www.palomahealth.com/pricing-hypothyroidism Paloma Complete Thyroid Blood Test Kit: https://www.palomahealth.com/home-thyroid-blood-test-kit

The practice of neurology is constantly changing, and the papers in this issue exemplify that trend. On this episode, journal editors Dr. Geraint Fuller and Prof. Philip Smith discuss their highlights from the latest issue of Practical Neurology, for February 2025. They begin with the editors' choice paper on stiff person syndrome, then speak about new guidance from the ABN on disease-modifying treatments for MS. There's also life-improving interventions for posterior cortical atrophy, changing attitudes towards stroke as a career option for neurologists, and management techniques for cryptococcal meningitis - including a resourceful substitute for India ink.  Read the issue: https://pn.bmj.com/content/25/1/1  Please subscribe to the Practical Neurology podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3vVPClm) or Spotify (https://spoti.fi/4baxjsQ). We'd love to hear your feedback on social media - @PracticalNeurol. Production by Letícia Amorim and Brian O'Toole. Editing by Brian O'Toole. Thank you for listening. 

Thank you for listening to this episode. We pray it will bless you in Jesus name. It is our hope and prayer that who ever listens to these sermons is blessed and draws closer to Jesus. If you are interested in a bible study or have questions, or need a prayer request please fill free to visit our website www.gvpcsafford.com or message us on any of our social media platforms. God bless.

About this episode: Hearing declines for everyone as we get older, no matter what we do. As it declines, it can cause health problems like cognitive decline and brain atrophy, and is directly linked with Alzheimer's. But there are ways to understand and reduce these impacts including over-the-counter hearing aids and a new app where people can test their hearing on their smartphone. In this episode: a conversation about a health issue that will impact all of us to some degree, and how technology is helping to address impacts early and upend the stigma of hearing loss. Guest: Dr. Frank Lin is the director of the Cochlear Center for Hearing and Public Health and a professor of otolaryngology, medicine, mental health, and epidemiology at the Johns Hopkins University Schools of Medicine and Public Health. Host: Lindsay Smith Rogers, MA, is the producer of the Public Health On Call podcast, an editor for Expert Insights, and the director of content strategy for the Johns Hopkins Bloomberg School of Public Health. Show links and related content: Episode transcript How and Why to Learn Your Hearing Numbers Download the Hearing Number app for iOS (App Store) or Android (Google Play) Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on X @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed

Send us a textIn today's episode called Common Causes of Deltoid Atrophy I talk about...1.Anatomy related to the deltoid musculature. 2. Causes of deltoid atrophy 3. Differential diagnoses and so much more! (Video) Patient with Axillary Nerve Palsy(Video) Patient with Shingles causing shoulder weakness✅Are you looking for One on one Coaching? We have it!✅ Hop onto our email list?

Every January, I like to make some predictions about the year ahead. Then, in my final post of the year, which this will probably be, I go back and review them. That's what we are doing today.Before I begin, just a couple of things:* In case you missed it, check out Friday's piece on North American tax loss selling. It has 9 ideas for short-term trades, which could come good by February.* And there is now a video version of "The Chainsaw and the Swamp: A Tale of Two Economies" for your Sunday morning viewing pleasure.Right. Here we go …Predictions are funny things. The more outlandish the prediction, the more entertaining the copy, but the less likely it is to actually happen. What is more important: getting lots of eyeballs or being right?I like this exercise because it demonstrates just how much perspective can change over time. While we can change strategy as events develop, what I wrote a year ago does not, so when you look back at stuff you got wrong, you can look foolish, even if you changed tack in real time. On the other hand, if you got stuff right, people go - well that was obvious.So the rules of my little game are this: I score two points for a direct hit, one for a good call, zero for a miss, and minus one for a "David Lammy on Mastermind" fail.I made 15 predictions. Here they are:1. The Great Decline goes on.I was pleased with this one, even if it was rather negative.“Everywhere the state's tentacles reach remains a drain on productivity. Our once-great institutions continue to fall apart, like zombie meth addicts, stumbling towards dysfunction... The ordinary worker desperately trying to improve his lot is bled dry by taxes, inflation, housing costs, and the voracious state monster. Fiat loses yet more of its purchasing power. The South Africanisation of everything continues.”Gosh, it's depressing and negative. Things may be changing on the other side of the pond, but they are not in Europe. Two points.2. Gold breaks out to new highs and goes to $2,400. And some. $2,790 was the high. We're now at $2,620. Two points.3. Bitcoin goes to new highs as well.Yup. We are at $98,000 as I write. $108,000 was the high. Two points.4. For reasons I don't understand, ethereum outperforms bitcoin.Ethereum always seems to move later in the cycle and by more, hence the prediction. But in 2024 bitcoin outperformed. Zero points.5. The US dollar trends sideways.It didn't. The US Dollar Index began the year at 100 and ended about 8% higher around 108. Another big fat zero.6. Sterling has problems.Cable began the year at around $1.27 and it's now at $1.25, having been as high as $1.34. So it's down a bit. But the eight-year cycle low that I am looking for has not materialized. I'm sure it's coming, but zero points.7. The Tories are eviscerated.Pleased with this one.They had their chance and they blew it. Come the General Election this year, the voters are unforgiving. … The SNP is similarly annihilated. The shortcomings of our political system are there for all to see. But nothing that needs to change does. Roughly 80% of the country did not vote Labour, yet they got 63% of the seats. Incredible. And they call it democracy. Two points.8. Uranium to hit $125/lb.Nope. The highest it got was $105/lb, and that was in January. It spent the rest of the year declining; it's now at $73. Minus one. Totally wrong.9. Fast and processed food companies have problems.I think I am early to this. Let's see what RFK does. But, by way of proxy, McDonald's is flat on the year; Burger King (Restaurant Brands International) is down 14%; KFC is off about 10%.Good call. Two points.Seed oils are losing.10. Good year for the Japanese yen. It has to go up sometime right? It's so cheap.Nope. It went down. Minus one.11. The S&P500 has a good year.I'll say. It's up 25%. Way above expectation. Two points.12. Small caps outperform.Apart from a brief spell in summer, they didn't. It feels like they are starting to, but nope. Zero points.13. UK house prices. Atrophy and stagnation, but no meltdownThat feels about right. About 50% of stuff on the market isn't selling, apparently. I'm not surprised; the cost of moving is so high. Two points.14. Silver. Can it stage a meaningful rally above $30?Nope, I said. It went to $34 in October. Now it's $29. Was that rally meaningful? Well, it did better than I thought it would. Zero points.15. Liverpool win the league; Sheffield United, Burnley, and Luton are relegated.Got the losers right but not the winners. 1 point.All in all, not a great showing. 13 points.Oddly enough, whenever I score low on the predictions, I have a much better year in the portfolio. That was the case this year, where we have had some real winners in the Flying Frisby: bitcoin and MicroStrategy, obviously, but also Lightbridge and Novavax too. Meanwhile, the low-risk Dolce Far Niente portfolio is rocking it.Happy Christmas everyone. Thank you for being a subscriber.And why not gift someone a subscription this Christmas?I'll have some predictions for 2025 early in the new year.Until next time.DominicPS Don't forget:* In case you missed it, Friday's piece on North American tax loss selling has 9 ideas for short-term trades, which could come good by February.* Plus the video version of "The Chainsaw and the Swamp: A Tale of Two Economies" for your Sunday morning viewing pleasure.Become enlightened. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.theflyingfrisby.com/subscribe

See omnystudio.com/listener for privacy information.

The boys head into Mid November with the very Thrash Metal Violent By Nature by Arizona's Atrophy!

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Alicja: Hi Dr.Cabral, Thanks to the knowledge you share I was able to improve my thyroid. I took your courses about thyroid and I listen to your podcast regularly. Last year when I tested my thyroid all the markers were in range, except for anty-TG. Having those antibodies still suggest I have Hashimoto. As you said on the podcast it may just take longer for the antibodies to disappear. I waited another year and retested my thyroid again. All looks good except I still test positive for Hashimoto. The latest test show anty-TG at 4.42 IU/ml, whereas the test year ago showed 9.35IU/ml. So there is a definite decline. My question: should I do nothing about it, because it takes years for the antibodies to disappear? Or the fact that I still have those antibodies for so long indicates a problem?     Alicja: Hi again, I also want to ask you about about two other things that were off my chart. I have very high levels of vit.B12. I don't supplement with B vitamins, but I take multivitamin daily. Since I saw very high levels of B12 on my bloodwork a couple of years ago, I decreased dosage of my multi and instead of taking a full dose, I take half dose or 2/3. Despite of that my latest test still shows very high and out of range B12 (654 pg/ml) Can this be toxic to my body? Have you ever heard of very high B12 levels indicating a cancer? Second: my prolactin levels are very low. What causes it and how can I correct that? I'm 41 yo, with improving health but still having some hormonal imbalances.     Madison: Hey Stephen! I got a steroid shot in my hip for a sinus infection 6 months ago, and the injection site is a large dimple now that's about twice the size of a quarter and pretty deep. I assume this is fat atrophy. Is there any way to help this condition? All I've read says fat graphs and Botox. Would red light therapy help? Is there a natural cream to stimulate the cells there to regenerate? Should I try like a detox mask on the area with bentonite clay? I need help I'm worried it will keep growing wider and deeper. Thanks for all you do!     Katie: Hello Dr. Cabral! I will always be a big fan and watch you daily! I feel that I have grown as a Nutritionist and have been able to help more people because of you. Keep fighting the good fight, we need you! I was wondering what your thoughts were on zeolite. I just started it and read that it can also remove parasite along with heavy metals. I did the Equi life metals and minerals test, and it showed high on mercury and aluminum. I am also going to do your heavy metal detox but want to do the maintenance with the zeolite. Always appreciate your feedback. Much love!     Mia: Hello! I discovered you on Mindpump and I love how you run all the tests with Sal, Justin and Adam. A few months ago you ran an epigenetics aging test to see what their biological age is. What test did you use with them?     Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!      - - - Show Notes and Resources: StephenCabral.com/3193 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Introduction: Kris and Jenn sit down with Karen Rellos, founder of Restored Hope Coaching and Redeeming Love Marriage Ministry. Karen, a certified betrayal trauma coach, joins the conversation to shed light on a topic that affects many relationships—Intimacy Deprivation, also known as Intimacy Atrophy (IA). With her extensive background in helping women navigate betrayal trauma, Karen offers valuable insights into the causes, impacts, and healing journey surrounding intimacy deprivation in relationships.Key Highlights:What is Intimacy Atrophy?Karen explains Intimacy Atrophy as a gradual loss of emotional, physical, or spiritual connection within a relationship. The term highlights the diminishing closeness and vulnerability in relationships, which can deeply impact both partners.Root Causes of Intimacy Deprivation:According to Karen, the root causes of Intimacy Atrophy often lie in unresolved emotional wounds, betrayal trauma, or avoidance of vulnerability. She discusses how individuals who struggle with intimacy deprivation may have past hurts or emotional blockages that prevent them from fully engaging in the relationship.Behaviors and Coping Mechanisms:Karen outlines common behaviors associated with intimacy deprivation, including emotional withdrawal, detachment, or the avoidance of meaningful connection. These coping mechanisms may develop as a way to shield oneself from emotional pain but ultimately contribute to a lack of closeness in the relationship.Impact on the Partner and Relationship:Karen explains how intimacy atrophy can lead to feelings of rejection, loneliness, and frustration in the partner who desires deeper connection, creating further strain and misunderstandings.Healing and Recovery:Karen emphasizes that healing from intimacy deprivation is possible. She describes the recovery process, which involves addressing the root causes, developing emotional awareness, and taking intentional steps toward rebuilding intimacy. A Word of Encouragement:In closing, Karen offers a heartfelt message to listeners, encouraging them to stay committed to the journey of healing and growth. She reminds them that it's possible to rekindle intimacy and build stronger, more fulfilling connections.Connect with Us:Karen Rellos: Restored Hope Coaching and Redeeming Love Marriage Ministry.Watermark CoachHealing with the HowiesFollow us on Instagram: @WatermarkCoachingThank you for listening! Don't forget to subscribe, rate, and review our podcast to stay updated on future episodes and help others find the help and support they deserve.

In this video, I'll be sharing the most effective way I've found to work with perimenopausal symptoms using herbs and understanding your unique energetic constitution or tissue state. As a clinical herbalist, I believe that finding the right match can make all the difference. I'll introduce you to American Ginseng (Panax quinquefolius)—an herb every woman entering perimenopause should consider for overall vitality, along with specific dosing tips. Plus, I'll dive into the four most common tissue states that often get out of balance during this stage: Excitation, Depression, Tension, and Atrophy. I'll guide you through how to identify these states in your body and share the best herbs to help restore balance, with dosing recommendations for each. I'll also cover commonly used herbs like Black Cohosh, Hops, and Dong Quai, explaining which specific patterns they work best with and how they can support your journey through perimenopause. I keep things lighthearted and easy to understand, so you can quickly discover the herbs that will help you feel more at ease and vibrant through this transition. Product Links: Herb for All Women - American Ginseng - Panax quinquefolius - https://mountainroseherbs.com/american-ginseng-extract For Hot/Excitation Types  Milky Oat Tops Tincture - https://amzn.to/4fjafJZ  Hops Tincture - https://amzn.to/48gRhkT  Hops Capsules - https://amzn.to/3YBhNC8 For Cold/Depressed Types  Angelica (archangelica - American or sinensis - Chinese) - https://mountainroseherbs.com/angelica-extract and https://amzn.to/3Yz4dix  Black Cohosh - https://www.herbalist-alchemist.com/shop-products-bck-black-cohosh-extract For Tension Types  Blue Vervain - Verbena hastata - https://www.herbalist-alchemist.com/shop-products-bvv-blue-vervain-extract  Hops Tincture - https://amzn.to/48gRhkT For Dry/Atrophy Types  Shatavari (Asparagus racemosus) - https://mountainroseherbs.com/shatavari  Marshmallow Root - https://mountainroseherbs.com/marshmallow-root

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Claaseen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, offered his insight on phase 1/2 data that was recently presented at the International Parkinson and Movement Disorder Society (MDS) Congress on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and considerations for its use, as well as the next steps in advancing care for patients with MSA as a whole. Looking for more movement disorders discussion? Check out the NeurologyLive® movement disorder clinical focus page. Episode Breakdown: 1:10 – Overviewing the conduct of the phase 1/2 studies 3:00 – Notable findings from data presented at MDS 4:30 – Mechanism of action behind ATH434 8:20 – Neurology News Minute 10:20 – Next steps in ATH434's development 11:15 – Current unmet needs for patients with MSA The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Removes Partial Hold for Myotonic Dystrophy Agent AOC 1001 FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pedatric Narcolepsy FDA Approves AbbVie's 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

n this article, featuring insights from expert guests Dr. James Fanelli and Dr. Roya Attar, we will explore the nature of Geographic Atrophy, its diagnosis, patient education, and current treatment options, offering eye care professionals actionable insights to serve their patients better.

St. Edith Stein's Science of the Cross (0:46).  Are you experiencing atrophy? (21:21).  One thing you need to know about the man who attempted to assassinate Trump that we should all learn from (38:44).     Resources mentioned :  St. Edith Stein Essays on Women  https://amzn.to/46BAJmy    Stories of those who have overcome looking at porn and how to stop too https://relevantradio.com/2024/07/its-just-porn/   Canopy Website  https://canopy.us/    Covenant Eyes Website  https://www.covenanteyes.com/   Kids book to help prevent porn:   Good Pictures Bad Pictures  https://www.defendyoungminds.com/product/good-pictures-bad-pictures    Wonderfully Made Babies: https://www.abebooks.com/9781491078181/Wonderfully-Made-Babies-Catholic-Perspective-1491078189/plp   Plunging Pornography:   https://shop.stewardshipmission.com/products/plunging-pornography

Dr Steve, Dr Scott, and Tacie discuss: DVT SVT motorcycles and thrombi memory diabetes and dementia somogyi effect half life of psilocybin smelling smoke (phantosmia) HRT and testicle atrophy Summary from the AI (HAHA): Speakers discussed the Fluid community's generosity, with viewers gifting memberships and super chats. They reminisced about the positive, fun atmosphere at the recent Hackamania event, where podcasters who mock others off-air were actually very friendly and welcoming. The speakers also mentioned upcoming events like DabbleCon, where one will be the announcer for the Dabby Awards When it came to addressing viewer questions, there was some back-and-forth, but they ultimately provided advice about tapering off gabapentin for a herniated cervical disc. The speakers discuss the different grades of spinal disc herniations and the various treatment options. For mild herniations, they suggest trying epidurals, gentle stretching, and neck exercises However, for severe herniations, they note that surgical intervention may be necessary. The speakers also address a question about Creutzfeldt-Jakob disease (CJD), a rare prion disease that can sometimes be transmitted through medical procedures, but is extremely uncommon. They reassure the listener that the risk of contracting CJD from their father's condition is very low The speakers discuss the potential risks of Creutzfeldt-Jakob disease (CJD), a rare and fatal prion disease. They explain that while CJD can sometimes occur sporadically or be inherited, it is unlikely to be spread through casual contact. The son is concerned about being tested, but the speakers advise that a genetic test is available if desired They also touch on the topic of sweating after exercise, noting that the body needs to dissipate the heat generated during physical activity. The speakers discuss the importance of sweating as a way to cool the body and regulate temperature. They also engage in some lighthearted banter, making references to their podcast and upcoming guests The speakers encourage listeners to take care of their health, such as checking for lumps, quitting smoking, and exercising regularly. Overall, the discussion provides practical advice while maintaining an entertaining and engaging tone. Please visit: simplyherbals.net/cbd-sinus-rinse (the best he's ever made. Seriously.) instagram.com/weirdmedicine (instagram by ahynesmedia.com!) x.com/weirdmedicine stuff.doctorsteve.com (it's back!) RIGHT NOW GET A NEW DISCOUNT ON THE ROADIE 3 ROBOTIC TUNER! roadie.doctorsteve.com (the greatest gift for a guitarist or bassist! The robotic tuner!) see it here: stuff.doctorsteve.com/#roadie Also don't forget: Cameo.com/weirdmedicine (Book your old pal right now because he's cheap! "FLUID!") GoFundMe for Brianna Shannon (Please help Producer Chris' daughter fight breast cancer!) Most importantly! CHECK US OUT ON PATREON!  ALL NEW CONTENT! Robert Kelly, Mark Normand, Jim Norton, Gregg Hughes, Anthony Cumia, Joe DeRosa, Pete Davidson, Geno Bisconte, Cassie Black ("Safe Slut"). Stuff you will never hear on the main show ;-) Learn more about your ad choices. Visit podcastchoices.com/adchoices

If you aren't regularly utilizing your Working Geniuses, you won't be able to take full advantage of your strengths.  This week, Pat and the team discuss atrophy as it relates to the Working Genius model.     To listen to the At the Table Podcast: tinyurl.com/atthetablepodcast